0
Reviews
Histamine-1 receptor antagonism for treatment of insomnia
Joseph P. Vande Griend; Sarah L. Anderson
J Am Pharm Assoc (2003) 2012;52:e210-e219. doi:10.1331/JAPhA.2012.12051

Abstract

Objectives  To evaluate the literature regarding the use of histamine-1 (H 1) receptor antagonists and to describe their role in the treatment of insomnia in adult patients, including the elderly.

Data sources  Literature was identified via PubMed and Medline through April 1, 2012, using the search terms insomnia and sleep, each individually combined with histamine antagonist, tricyclic antidepressant, trazodone, mirtazapine, doxepin, amitriptyline, nortriptyline, trimipramine, doxylamine, diphenhydramine, and antihistamine.

Study selection and data extraction  Data included randomized double-blind trials that statistically evaluated H 1 receptor antagonist treatment in patients with insomnia compared with a placebo control or Food and Drug Administration–approved insomnia treatment. Trials selected evaluated sleep latency, wake after sleep onset, total sleep time, number of awakenings, and/or sleep efficiency in a subjective or objective manner. A total of 65 trials were evaluated, and 16 met inclusion criteria.

Data synthesis  With the exception of low-dose doxepin (Silenor—Somaxon), trials evaluating the clinical effectiveness of H 1 receptor antagonists show mixed results and are limited by sample size and generalizability. Large, randomized, appropriately controlled trials are lacking, making it difficult to define the safety and efficacy of these agents. In contrast, low-dose doxepin has been shown to provide consistent sleep benefit compared with placebo.

Conclusion  Over-the-counter antihistamines may have a role for short-term insomnia treatment in younger adults, but tolerance develops rapidly. Mirtazapine should not be used solely for the treatment of insomnia. Sedating antidepressants can be considered after failure of first-line insomnia treatments. Patients taking these agents chronically should be evaluated for continued efficacy and potential harm. Low-dose doxepin may have a unique role in the treatment of insomnia in elderly patients given its tolerability, documented efficacy, and lack of important adverse effects.

Sign In
APhA Members 
Welcome to JAPhA.org! Please log in below using your APhA username and password. Update your APhA profile.
Not a Subscriber
New to JAPhA? Become an APhA member to receive a full subscription to both the print and online editions.

OR

Register for a FREE limited account to benefit from personalization features such as alerts.

References

   Summers MO, Crisostomo MI, Stepanski EJ.  Recent developments in the classification, evaluation, and treatment of insomnia.  Chest.  2006; 130: 276– 86. [PubMed]
 
   Ohayon MM.  Epidemiology of insomnia: what we know and what we still need to learn.  Sleep Med Rev.  2002; 6: 97– 111. [PubMed]
 
   Bhat A, Shafi F, Solh AA El.  Pharmacotherapy of insomnia.  Expert Opin Pharmacother.  2008; 9: 351– 62. [PubMed]
 
   Ozminkowski RJ, Wang S, Walsh JK.  The direct and indirect costs of untreated insomnia in adults in the United States.  Sleep.  2007; 30: 263– 73. [PubMed]
 
   Walsh JK, Engelhardt CL.  The direct economic costs of insomnia in the United States for 1995.  Sleep.  1999; 22( suppl 2): S386– 93. [PubMed]
 
   Stahl SM.  Stahl's essential psychopharmacology. 3rd ed.  New York:  Cambridge University Press;  2008.
 
   Ramesh V, Thakkar MM, Strecker RE, et al.  Wakefulness-inducing effects of histamine in the basal forebrain of freely moving rats.  Behav Brain Res.  2004; 152: 271– 8. [PubMed]
 
   Strecker RE, Nalwalk J, Dauphin LJ, et al.  Extracellular histamine levels in the feline preoptic/anterior hypothalamic area during natural sleep-wakefulness and prolonged wakefulness: an in vivo microdialysis study.  Neuroscience.  2002; 113: 663– 70. [PubMed]
 
   Wiegand MH.  Antidepressants for the treatment of insomnia: a suitable approach? Drugs.  2008; 68: 2411– 7. [PubMed]
 
   Stahl SM.  Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines.  CNS Spectr.  2008; 13: 1027– 38. [PubMed]
 
   Mendelson WB, Roth T, Cassella J, et al.  The treatment of chronic insomnia: drug indications, chronic use and abuse liability: summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium.  Sleep Med Rev.  2004; 8: 7– 17. [PubMed]
 
   Schutte-Rodin S, Broch L, Buysse D, et al.  Clinical guideline for the evaluation and management of chronic insomnia in adults.  J Clin Sleep Med.  2008; 4: 487– 504. [PubMed]
 
   Morin CM, Koetter U, Bastien C, et al.  Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial.  Sleep.  2005; 28: 1465– 71. [PubMed]
 
   Glass JR, Sproule BA, Herrmann N, et al.  Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial.  J Clin Psychopharmacol.  2008; 28: 182– 8. [PubMed]
 
   Rickels K, Morris RJ, Newman H, et al.  Diphenhydramine in insomniac family practice patients: a double-blind study.  J Clin Pharmacol.  1983; 23: 234– 42. [PubMed]
 
   Meuleman JR, Nelson RC, RL Jr Clark.  Evaluation of temazepam and diphenhydramine as hypnotics in a nursing-home population.  Drug Intell Clin Pharm.  1987; 21: 716– 20. [PubMed]
 
   Sjoqvist F, Lasagna L.  The hypnotic efficacy of doxylamine.  Clin Pharmacol Ther.  1967; 8: 48– 54. [PubMed]
 
   Winokur A, Sateia MJ, Hayes JB, et al.  Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study.  Biol Psychiatry.  2000; 48: 75– 8. [PubMed]
 
   Winokur A, NA 3rd DeMartinis, McNally DP, et al.  Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia.  J Clin Psychiatry.  2003; 64: 1224– 9. [PubMed]
 
   Cankurtaran ES, Ozalp E, Soygur H, et al.  Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine.  Support Care Cancer.  2008; 16: 1291– 8. [PubMed]
 
   Kim SW, Shin IS, Kim JM, et al.  Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression.  Psychiatry Clin Neurosci.  2008; 62: 75– 83. [PubMed]
 
   Radhakishun FS, van den Bos J, van der Heijden BC, et al.  Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens.  J Clin Psychopharmacol.  2000; 20: 531– 7. [PubMed]
 
   Ruigt GS, Kemp B, Groenhout CM, et al.  Effect of the antidepressant Org 3770 on human sleep.  Eur J Clin Pharmacol.  1990; 38: 551– 4. [PubMed]
 
   Shen J, Chung SA, Kayumov L, et al.  Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine.  Can J Psychiatry.  2006; 51: 27– 34. [PubMed]
 
   Schittecatte M, Dumont F, Machowski R, et al.  Effects of mirtazapine on sleep polygraphic variables in major depression.  Neuropsychobiology.  2002; 46: 197– 201. [PubMed]
 
   Aslan S, Isik E, Cosar B.  The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers.  Sleep.  2002; 25: 677– 9. [PubMed]
 
   Bon O Le, Murphy JR, Staner L, et al.  Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations.  J Clin Psychopharmacol.  2003; 23: 377– 83. [PubMed]
 
   Walsh JK, Erman M, Erwin CW, et al.  Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia.  Human Psychopharmacol.  1998; 13: 191– 8.
 
   Roth AJ, McCall WV, Liguori A.  Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs.  J Sleep Res.  2011; 20: 552– 8. [PubMed]
 
   Stein MD, Kurth ME, Sharkey KM, et al.  Trazodone for sleep disturbance during methadone maintenance: a double-blind, placebo-controlled trial.  Drug Alcohol Depend.  2011; 120: 65– 73. [PubMed]
 
   Riemann D, Voderholzer U, Cohrs S, et al.  Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study.  Pharmacopsychiatry.  2002; 35: 165– 74. [PubMed]
 
   Hajak G, Rodenbeck A, Voderholzer U, et al.  Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study.  J Clin Psychiatry.  2001; 62: 453– 63. [PubMed]
 
   Roth T, Rogowski R, Hull S, et al.  Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia.  Sleep.  2007; 30: 1555– 61. [PubMed]
 
   Scharf M, Rogowski R, Hull S, et al.  Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study.  J Clin Psychiatry.  2008; 69: 1557– 64. [PubMed]
 
   Krystal AD, Durrence HH, Scharf M, et al.  Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia.  Sleep.  2010; 33: 1553– 61. [PubMed]
 
   Roth T, Durrence H Heith, Jochelson P, et al.  Efficacy and safety of doxepin 6 mg in a model of transient insomnia.  Sleep Med.  2010; 11: 843– 7. [PubMed]
 
   Krystal AD, Lankford A, Durrence HH, et al.  Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia.  Sleep.  2011; 34: 1433– 42. [PubMed]
 
   Lankford A, Rogowski R, Essink B, et al.  Efficacy and safety of doxepin 6mg in a four-week outpatient trial of elderly adults with chronic primary insomnia.  Sleep Med.  2011; 13: 133– 8. [PubMed]
 
   American Geriatrics Society 2012 Beers Criteria Update Expert Panel.  American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults.  J Am Geriatr Soc.  2012; 60: 616– 31. [PubMed]
 
   Micromedex Healthcare Series.  Doxepin, diphenhydramine, and trazodone. Accessed at www.thomsonhc.com/home/dispatch,  March 5, 2012.
 
   Schweitzer PK, Muehlbach MJ, Walsh JK.  Sleepiness and performance during three-day administration of cetirizine or diphenhydramine.  J Allergy Clin Immunol.  1994; 94: 716– 24. [PubMed]
 
   Manning C, Scandale L, Manning EJ, Gengo FM.  Central nervous system effects of meclizine and dimenhydrinate: evidence of acute tolerance to antihistamines.  J Clin Pharmacol.  1992; 32: 996– 1002. [PubMed]
 
   Bye CE, Claridge R, Peck AW, Plowman F.  Evidence for tolerance to the central nervous effects of the histamine antagonist, triprolidine, in man.  Eur J Clin Pharmacol.  1977; 12: 181– 6. [PubMed]
 
   Levander S, Stahle-Backdahl M, Hagermark O.  Peripheral antihistamine and central sedative effects of single and continuous oral doses of cetirizine and hydroxyzine.  Eur J Clin Pharmacol.  1991; 41: 435– 9. [PubMed]
 
   Monti JM, Monti D.  Histamine H1 receptor antagonists in the treatment of insomnia: is there a rational basis for use? CNS Drugs.  2000; 13: 87– 96.
 
   Stimmel GL, Dopheide JA, Stahl SM.  Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects.  Pharmacotherapy.  1997; 17: 10– 21. [PubMed]
 
   Thase ME.  Antidepressant treatment of the depressed patient with insomnia.  J Clin Psychiatry.  1999; 60( suppl 17): 28– 31. [PubMed]
 
   Fox CB, Treadway AK, Blaszczyk AT, Sleeper RB.  Megestrol acetate and mirtazapine for the treatment of unplanned weight loss in the elderly.  Pharmacotherapy.  2009; 29: 383– 97. [PubMed]
 
   Roy AN, Smith M.  Prevalence and cost of insomnia in a state Medicaid fee-for-service population based on diagnostic codes and prescription utilization.  Sleep Med.  2010; 11: 462– 9. [PubMed]
 
   Mendelson WB.  A review of the evidence for the efficacy and safety of trazodone in insomnia.  J Clin Psychiatry.  2005; 66: 469– 76. [PubMed]
 
   Buscemi N, Vandermeer B, Friesen C, Bialy L.  The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs.  J Gen Intern Med.  2007; 22: 1335– 50. [PubMed]
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Please read the other comments before you post yours. Comments are moderated and will appear on the site at the discertion of the editorial staff.
* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content

Customize your page view by dragging & repositioning the boxes below.

Topic Collections
PubMed Articles
Advertisement
 
  • Print
  • PDF Download
  • Email
  • Share
  • Get Citation
  • Submit Comment
  • Article Alerts
    Please Wait... Processing your request... Please Wait.
    You must sign in to sign-up for alerts.

    Please confirm that your email address is correct, so you can successfully receive this alert.

  • Letters To Editor
  • Reprints